At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02565 PEGBIO CO-B
Market Closed 06-18 16:08:08
6.130
-0.070
-1.13%
High6.590Low6.090Vol17.66M
Open6.240D1 Closing6.200Amplitude8.06%
Mkt Cap2.40BTradable Cap1.74BTotal Shares391.00M
T/O111.98MT/O Rate6.22%Tradable Shares284.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure
Market Focus  ·  06-16
Movement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure
PegBio Receives HK$61 Million in Royalty Payment Over Drug Licensing Deal
MT Newswires Live  ·  06-08
PegBio Receives HK$61 Million in Royalty Payment Over Drug Licensing Deal
Movement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma
Market Focus  ·  06-08
Movement Alert｜PegBio Rises 8.37% in Regular Trading, Boosted by HKD 61 Million Commercialization Milestone Payment from Tengrui Pharma
PegBio Co-B Shares Surge Over 6% Following Receipt of HKD 61 Million Initial Royalty Payment for Commercialization of Drug Candidate
Stock News  ·  06-08
PegBio Co-B Shares Surge Over 6% Following Receipt of HKD 61 Million Initial Royalty Payment for Commercialization of Drug Candidate
PEGBIO CO-B Receives First Commercialization Milestone Payment of HK$61 Million for Weipenataide from Tengrui Pharmaceutical
Stock News  ·  06-05
PEGBIO CO-B Receives First Commercialization Milestone Payment of HK$61 Million for Weipenataide from Tengrui Pharmaceutical
PegBio receives first HK$ 61 million royalty payment from Tenry Pharma under Visepegenatide deal
Reuters  ·  06-05
PegBio receives first HK$ 61 million royalty payment from Tenry Pharma under Visepegenatide deal
Movement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound
Market Focus  ·  06-04
Movement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound
PegBio Reports Stable Share Capital in May 2026 and Affirms Public Float Compliance
Bulletin Express  ·  06-03
PegBio Reports Stable Share Capital in May 2026 and Affirms Public Float Compliance
PEGBIO CO-B Shares Surge Over 13% in Session as CR059 Accepted for EASD 2026 and Oral Presentation
Deep News  ·  06-02
PEGBIO CO-B Shares Surge Over 13% in Session as CR059 Accepted for EASD 2026 and Oral Presentation
PEGBIO CO-B Shares Surge Over 13% as CR059 Research Accepted for Presentation at EASD 2026
Stock News  ·  06-02
PEGBIO CO-B Shares Surge Over 13% as CR059 Research Accepted for Presentation at EASD 2026
Movement Alert｜PegBio Pharma-B Rises 10.55% in Regular Trading, CR059 EASD Oral Presentation Selection and Buyback Plan Boost Sentiment
Market Focus  ·  06-02
Movement Alert｜PegBio Pharma-B Rises 10.55% in Regular Trading, CR059 EASD Oral Presentation Selection and Buyback Plan Boost Sentiment
PegBio Sets 24 June 2026 for 2025 AGM; Capital Increase, Share Mandates and 2026 Budget on Ballot
Bulletin Express  ·  06-01
PegBio Sets 24 June 2026 for 2025 AGM; Capital Increase, Share Mandates and 2026 Budget on Ballot
PEGBIO's Innovative GLP-1 Analog CR059 Achieves Acceptance for Presentation at Prestigious EASD 2026 Conference
Stock News  ·  06-01
PEGBIO's Innovative GLP-1 Analog CR059 Achieves Acceptance for Presentation at Prestigious EASD 2026 Conference
PegBio’s CR059 Gets EASD 2026 Oral Presentation Slot, Reinforcing Circular-RNA GLP-1 Leadership
Bulletin Express  ·  06-01
PegBio’s CR059 Gets EASD 2026 Oral Presentation Slot, Reinforcing Circular-RNA GLP-1 Leadership
PegBio says circular RNA-encoded GLP-1 candidate CR059 wins oral presentation slot at EASD 2026
Reuters  ·  06-01
PegBio says circular RNA-encoded GLP-1 candidate CR059 wins oral presentation slot at EASD 2026
PEGBIO CO-B's GLP-1 Agonist Vepetide Injection Included in 2026 National Reimbursement Drug List Pre-Communication Process
Stock News  ·  05-28
PEGBIO CO-B's GLP-1 Agonist Vepetide Injection Included in 2026 National Reimbursement Drug List Pre-Communication Process
Stock Track | PegBio Pharma Soars 15.53% Intraday on Technical Rebound After IPO Lock-up Expiry Selloff
Stock Track  ·  05-28
Stock Track | PegBio Pharma Soars 15.53% Intraday on Technical Rebound After IPO Lock-up Expiry Selloff
Movement Alert｜PegBio Pharma Rises 10.77% in Regular Trading, Technical Rebound After IPO Lock-up Expiry Selloff
Market Focus  ·  05-28
Movement Alert｜PegBio Pharma Rises 10.77% in Regular Trading, Technical Rebound After IPO Lock-up Expiry Selloff
Movement Alert｜PegBio Pharma Intraday Decline 15.99% in Regular Trading, Lock-Up Expiry on IPO Anniversary Triggers Selling Pressure
Market Focus  ·  05-27
Movement Alert｜PegBio Pharma Intraday Decline 15.99% in Regular Trading, Lock-Up Expiry on IPO Anniversary Triggers Selling Pressure
Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum
Stock Track  ·  05-22
Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum

Introduction

Company Name.
PEGBIO CO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
PegBio Co Ltd is a China-based company principally engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).
Issue price:
--